Hospital
Memorial Hospital of Boscobel
Memorial Hospital of Boscobel was paid $5.40M by Medicaid between Jan 2018 and Dec 2024, across 104 billing codes. Its largest line is 99283, emergency room visit (moderate) — 18% of everything it billed.
33Billing provider infoMEMORIAL HOSPITAL OF BOSCOBEL
BOSCOBEL, WI 53805
BOSCOBEL, WI 53805
33aNPI1760459846assigned 03/07/2006
33bProvider typeCritical Access Hospital
28Total paid$5.40M
24GClaims110,396
24DCodes billed104
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#24 of 48
Median peer was paid$4.30M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,767 | $620K | |
| 2019 | 12,541 | $502K | |
| 2020 | 12,691 | $511K | |
| 2021 | 18,263 | $715K | |
| 2022 | 18,675 | $1.03M | |
| 2023 | 18,474 | $1.10M | |
| 2024incomplete | 17,985 | $923K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 5,966 | 3,779 | $977K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 4,873 | 3,047 | $635K |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 1,536 | 1,120 | $632K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 2,812 | 2,252 | $620K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 9.3% | 3,586 | 2,875 | $504K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.6% | 1,532 | 991 | $303K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 4.7% | 2,909 | 2,401 | $253K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 1,135 | 1,015 | $234K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.3% | 1,772 | 1,160 | $234K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.6% | 961 | 559 | $193K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 773 | 506 | $181K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 1,395 | 1,206 | $91K |
92 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 2,778 | $90K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,202 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 455 | $37K |
| 80053 | Comprehensive metabolic panel | <1% | 4,905 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,890 | $28K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,285 | $27K |
| 11721 | <1% | 1,184 | $25K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,614 | $16K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,107 | $16K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,213 | $14K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,897 | $14K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 313 | $13K |
| 84484 | <1% | 2,650 | $12K | |
| 80061 | Lipid panel | <1% | 885 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,205 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 910 | $11K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 43 | $10K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 289 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,563 | $7K |
| 82565 | <1% | 1,911 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 26 | $7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 384 | $7K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 982 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,562 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 123 | $5K |
| 81001 | <1% | 2,497 | $5K | |
| 84145 | <1% | 486 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,656 | $5K |
| 83690 | <1% | 1,159 | $5K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 446 | $5K |
| 83605 | <1% | 939 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 18 | $4K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 77 | $3K |
| 87081 | <1% | 405 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,996 | $3K |
| 83735 | <1% | 774 | $3K | |
| 80051 | <1% | 541 | $3K | |
| 84460 | <1% | 616 | $2K | |
| 85610 | <1% | 875 | $2K | |
| 81003 | <1% | 1,331 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 12 | $2K |
| 87077 | <1% | 521 | $2K | |
| 81025 | <1% | 293 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $2K |
| 85379 | <1% | 325 | $2K | |
| 87040 | <1% | 425 | $1K | |
| Q3014 | Telehealth originating site facility fee | <1% | 307 | $1K |
| 87186 | <1% | 267 | $1K | |
| 85027 | <1% | 224 | $1K | |
| 84703 | <1% | 155 | $972.35 | |
| 82962 | <1% | 573 | $959.31 | |
| 86140 | <1% | 274 | $885.23 | |
| 0011A | <1% | 35 | $844.66 | |
| 82947 | <1% | 214 | $752.23 | |
| 96127 | <1% | 21 | $741.20 | |
| 84450 | <1% | 154 | $580.96 | |
| 0012A | <1% | 17 | $552.64 | |
| 90686 | <1% | 14 | $472.35 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,045 | $470.74 |
| 84132 | <1% | 108 | $445.78 | |
| 84439 | <1% | 66 | $438.47 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,613 | $349.82 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,179 | $294.93 |
| 73630 | <1% | 42 | $244.47 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 918 | $238.38 |
| 82247 | <1% | 58 | $176.96 | |
| 84075 | <1% | 45 | $154.81 | |
| 82728 | <1% | 17 | $126.72 | |
| 82040 | <1% | 27 | $118.87 | |
| 82043 | <1% | 14 | $104.99 | |
| 82310 | <1% | 29 | $98.11 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 23 | $88.17 |
| 86900 | <1% | 14 | $75.72 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,070 | $74.19 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,482 | $73.84 |
| 83550 | <1% | 14 | $72.24 | |
| 83540 | <1% | 14 | $53.52 | |
| 86850 | <1% | 14 | $43.04 | |
| 84520 | <1% | 16 | $36.72 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 952 | $24.76 |
| 86901 | <1% | 14 | $24.72 | |
| 91301 | <1% | 22 | $19.73 | |
| 85652 | <1% | 15 | $19.53 | |
| 80050 | General health panel | <1% | 15 | $16.86 |
| A9270 | Non-covered item or service | <1% | 2,839 | $15.60 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 899 | $13.58 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 437 | $2.35 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 16 | $0.79 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 30 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 22 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 15 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOIGENZAHN, JENNIFER (FINANCE ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Memorial Hospital of Boscobel | Boscobel, WI | $123K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.